Key players are enhancing their range of testing options for real-time PCR instruments by increasing R&D activities for the development of kits that target emerging diseases or by entering into agreements with other kit manufacturing companies. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.Ĭompanies are expanding their product portfolios with the acquisition of smaller companies. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period.
Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results.
0 kommentar(er)
